Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care

Slide: 5 of 36

FDA Approved Indications for rFVIIa

Since 1999, the FDA has approved four separate applications that have gradually expanded the scope of rFVIIa use in hemophilia:

1.Hemophilia A or B with inhibitors for bleeding episodes (March 25, 1999).
2.Bleeding and surgery in congenital factor VII deficiency (July 11, 2005).
3.Surgery and invasive procedures in hemophilia A or B with inhibitors (August 12, 2005).
4.Bleeding and surgery in acquired hemophilia (October 13, 2006).